The Supreme Court on Thursday allowed access to medication abortion via telemedicine and by mail to continue, blocking a decision at the appellate court level that had restricted the drug.
The justices granted emergency requests from the makers of mifepristone, Danco Laboratories LLC and GenBioPro Inc., after the New Orleans-based 5th U.S. Circuit Court of Appeals on May 1 established an in-person requirement for dispensing of the medication, ruling that distribution by mail violates Louisiana’s abortion ban.
The stay retains the status quo in the U.S. and remains in effect pending disposition of the appeal at the 5th Circuit.
